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Background. Unlike in most adult-onset cancers, an association between typical paediatric neoplasms and inﬂammatory triggers is
rare.Westudiedwhether immunesystem-relatedgenesareactivatedandhaveprognosticsigniﬁcanceinEwing’ssarcomafamilyof
tumors (ESFTs). Method. Data analysis was performed on gene expression proﬁles of 44 ESFT patients, 11 ESFT cell lines, and 18
normal skeletal muscle samples. Diﬀerential expression of 238 inﬂammation and 299 macrophage-related genes was analysed by
t-test, and survival analysis was performed according to gene expression. Results. Inﬂammatory genes are activated in ESFT patient
samples, as 38 of 238 (16%) inﬂammatory genes were upregulated (P<0.001) when compared to cell lines. This inﬂammatory
gene activation was characterized by signiﬁcant enrichment of macrophage-related gene expression with 58 of 299 (19%) of genes
upregulated (P<0.001). High expression of complement component 5 (C5) correlated with better event-free (P = 0.01) and
o v e r a l ls u r v i v a l( P = 0.004) in a dose-dependent manner. C5 and its receptor C5aR1 expression was veriﬁed at protein level by
immunohistochemistry on an independent ESFT tumour tissue microarray. Conclusion. Immune system-related gene activation is
observedinESFTpatientsamples,andprognosticallysigniﬁcantinﬂammatorygenes(C5,JAK1,andIL8)forESFTwereidentiﬁed.
1.Introduction
Adult cancer is frequently preceded by a period of prolonged
chronic inﬂammation caused by infectious microbial agents
(Hepatitis B or C, human papillomavirus, Ebstein-Barr
virus, and Helicobacter pylori) and other physical agents
or irritants (repeated UV exposure, prolonged exposure to
tobacco smoke, or asbestos ﬁbers) [1]. Such preneoplastic
inﬂammatory period may persist for several decades before a
state of genomic instability and the full neoplastic phenotype
is acquired. The role of the chronic inﬂammatory microen-
vironment as a causative factor is strongly supported also by
ﬁndings that regular use of nonsteroidal anti-inﬂammatory
drugs(NSAIDs)isassociatedwithareducedincidenceofcol-
orectal, breast, and gastric cancer [2–4]. On the contrary, an
association between typical paediatric neoplasias (for exam-
ple small round blue cell tumours) and inﬂammatory trig-
gers is very rare. Whereas the expression of cyclooxygenase-
2 (COX-2), an inducible enzyme active in inﬂammatory
sites, has a tumour promoting activity in several adult
cancers, studies in paediatric osteosarcoma, Ewing sarcoma,
and rhabdomyosarcoma have failed to show any correlation
between the activity of COX-2 and patient outcome [5].
The inﬂammatory preneoplastic period that is typical in
adult but uncommon in paediatric cancers could result in
qualitativeandquantitativediﬀerencesintumourinﬁltrating
leukocytes. This hypothesis was conﬁrmed in our previous
immunohistochemistry study in which we found that in
adult tumours inﬁltrating leukocytes were composed of
diverse leukocyte types, but in paediatric tumours, the inﬁl-
trating cells were predominantly macrophages, and dendritic
c e l l sw e r ev i r t u a l l ya b s e n t[ 6]. The ﬁnding suggested that in2 ISRN Oncology
typical paediatric tumours that evidently are not originating
from chronic inﬂammation, the immune system may not
have similarly signiﬁcant role either in carcinogenesis or
immune surveillance of tumours as in adult cancer [1].
Microarray-based gene expression proﬁling provides
data about genes that are either over- or underexpressed in
studied samples. Ewing sarcoma family of tumours (ESFTs)
represent typical paediatric small-round blue cell tumours.
We postulated that by comparing gene expression proﬁles
of clinical ESFT tumour samples and Ewing sarcoma cell
lines, we could reveal inﬂammatory gene signals derived
from ESFT-associated immune component. In addition,
gene expression diﬀerences between clinical ESFT samples
and normal muscle tissues were determined to identify
inﬂammatory genes that are functional in ESFT tumours
but not in surrounding tissues. Prognostic signiﬁcance of
these ﬁndings was assessed by analysing cumulative outcome
data of the patients. Our results suggest that high local
production of complement component 5 (C5) and janus
kinase 1 (JAK1) at tumour site associates with better survival
of ESFT patients, whereas locally produced interleukin 8
(IL8) is detrimental.
2. Patientsand Methods
2.1. Patients and Clinical Samples. The majority of ESFT
patients were diagnosed with Ewing sarcoma (n = 32),
ten with primitive neuroectodermal tumour (PNET), and
two with Askin’s tumour (Table 1). The patient material for
study was taken prior to any treatment in 29 cases, and
in 15 cases, chemotherapeutics, radiation therapy, and/or
surgical treatment was applied before material was collected
(see Table 1 for details). All patients were treated within
controlled prospective trials [7, 8]. Of the 44 samples used
in data analysis, 32 were primary tumours, ﬁve recurrences,
and seven metastases. The mean age of the patients was 17.9
years, ranging from 4 to 34 years and the male to female
ratio was 1.75 to 1. Median follow up was 44.8 months.
For detailed data on patient material, see Table 1.T h i ss t u d y
was reviewed and approved by the Ethical Review Board
of Helsinki University Central Hospital (decision no. 329
HUS/E0/05 and 328 HUS/W0/05). In order to ensure the
anonymity of the patients, a generic sample code was given
to each specimen, and all personal data was eliminated when
subjected to this research.
2.2. Expression Data. Data analysis was performed on
Aﬀymetrix Human Genome U133 Plus 2.0 gene expression
proﬁles of 44 ESFT patient samples previously published
by Savola et al. [9], and original microarray data of these
samples is available at gene expression omnibus (GEO)
[10] with accession number GSE17679. Prior to expression
analysis, patient material was checked to contain tumour
tissue >75% using histological analysis. In brief, 5μgo f
total RNA was reverse transcribed to cDNA using One-Cycle
cDNA Synthesis Kit (Aﬀymetrix), according to the man-
ufacturer’s GeneChip One-Cycle Target Labeling-protocol.
Biotin-labeling of antisense cRNA was carried out using IVT
LabelingKit(Aﬀymetrix).ThelabeledandfragmentedcRNA
(15μgofeach)washybridizedfor16hat45◦Cinahybridiza-
tion oven 640 (60rpm). Washing and staining of the arrays
with streptavidin-phycoerythrin (SAPE) was completed in
a Fluidics Station 450 (Aﬀymetrix). The arrays were then
scanned using a confocal laser GeneChip Scanner 3000, and
images were analyzed using GeneChip Operating Software
(GCOS; Aﬀymetrix, Sacramento, Calif, USA). Expression
proﬁles (n = 11) of ESFT cell line samples (6647, IOR/BRZ,
IOR/CAR, IOR/CLB, IOR/NGR, IOR/RCH, LAP35, RDES,
SKES1, SKNMC, and TC71) were produced by the same
method as described previously [9], and they are found at
GEO with accession number GSE17679. Expression proﬁles
(n = 18) of normal skeletal muscle tissue were selected from
GEO with accession no. GSE6798 and GSE3526.
2.3. Annotated Gene Lists and Gene Expression Signatures.
First, a collection of 238 genes putatively related to inﬂam-
mation was constructed by literature review and included,
for example, genes-encoding chemokines, chemokine recep-
tors, cytokines, cytokine receptors, signalling molecules, and
Toll-like receptors (see Supplemental data 1 which available
online at: doi: 10.5402/2011/168712). This step was per-
formed before looking at the ESFT expression data. Finally, a
gene expression signature was derived from macrophages. A
list of 299 genes expressed in macrophage cells was extracted
from the SymAtlas [11], which contains Aﬀymetrix U133
gene expression data from 122 normal cells and 90 cancer
cell lines. There were 18 samples from the immune system-
speciﬁc cell types of which two were CD14 positive cells.
Macrophage-speciﬁc gene signature (n = 299) was extracted
by ﬁltering SymAtlas data according to the present/absent
ﬂags of MAS5 (Microarray Suite 5.0 statistical algorithm)
preprocessed Aﬀymetrix data. To be selected for inclusion in
the macrophage speciﬁc gene list, probe sets were required to
be presentin both macrophagesamples.In addition, selected
p r o b es e t sw e r er e q u i r e dt ob ea b s e n ti na tl e a s t5 0 %o ft h e
samples of nonmacrophage immune system cells, 50% of
normal cells and 50% of NCI 60 cell lines.
2.4.AnalysisofDiﬀerentialGeneExpressionandInﬂammatory
Response. All known protein coding genes were extracted
from the NCBI38 data set in the Ensembl database [12], and
a single Aﬀymetrix probe set was chosen to represent each
gene. Out of the probe sets annotated with a particular gene,
the one with highest average expression level was chosen to
represent that gene so that unique probe sets were given a
priority (i.e., all genes that were annotated to match at least
oneuniqueprobesetarerepresentedbysuchprobesets).The
purpose for taking protein coding genes as a base set instead
of working directly at the Aﬀymetrix probe set level was to
remove potential bias caused by the manually constructed
inﬂammation gene list consisting solely of genes known to
code proteins. The macrophage list deﬁned at the probe set
level was transformed to the gene level using the Ensembl
annotations. All genes that included any of the macrophage
probe sets as a potential match were included to the list used
in the data analysis, resulting in a list of 299 genes.
Diﬀerential expression was measured for each gene
by a combination of two-sided t-test and fold changeISRN Oncology 3
Table 1: Clinical data of 44 ESFT patient samples.
Sample code Diagnosis State Age Sex EFS OVS Status Treatment
R194 Ewing Primary 32 F 11,7 15,6 Dead −
R196 Ewing Primary 5 M 14,0 20,7 Dead −
R29 Ewing Primary 21 M 4,6 4,6 Dead −
R30 Ewing Primary 26 F 28,6 48,9 NED +
R33 Ewing Primary 15 M 16,6 16,6 Dead −
R34 Ewing Primary 18 M 19,4 56,5 AWD +
R35 Ewing Primary 16 F 10,0 13,6 Dead +
R37 Ewing Primary 11 M 9,8 9,8 Dead +
R38 Ewing Primary 23 M 11,3 11,3 Dead −
R39 Ewing Primary 16 F 47,0 47,0 Dead −
R40 Ewing Primary 24 M 18,2 117,3 NED −
R41 Ewing Primary 15 M 125,1 125,1 NED −
R42 Ewing Primary 18 M 192,2 192,2 NED −
R43 Ewing Recurrence 17 F 24,8 35,7 Dead +
R44 Ewing Recurrence 30 F 19,8 25,6 Dead +
R45 Askin Recurrence 15 M 17,9 24,6 Dead +
R46 PNET Primary 7 F 22,1 64,2 Dead −
R48 Ewing Metastasis 17 M 31,6 46,2 Dead +
R49 Ewing Metastasis 34 M 18,6 126,2 NED +
R50 PNET Metastasis 16 M 58,3 99,3 Dead −
R51 Askin Primary 24 M 4,6 10,9 Dead +
R52 Ewing Recurrence 22 F 14,4 23,2 Dead +
R53 Ewing Primary 19 F 87,7 87,7 NED −
R54 Ewing Recurrence 22 M 25,9 61,5 Dead +
R55 PNET Metastasis 16 F 6,8 8,5 Dead −
R57 Ewing Primary 11 M 2,0 8,7 Dead −
R58 Ewing Primary 22 M 13,4 13,4 Dead −
R60 Ewing Primary 12 M 121,5 121,5 NED −
R61 Ewing Primary 15 M 16,2 16,2 NED −
R62 Ewing Primary 16 M 117,6 117,6 NED −
R63 Ewing Primary 13 M 43,4 43,4 NED −
R64 Ewing Primary 25 M 15,3 21,3 Dead −
R65 Ewing Primary 20 F 11,0 11,0 Dead −
R67 Ewing Primary 14 M 16,7 29,4 Dead −
R69 Ewing Primary 9 F 62,6 62,6 NED −
R72 PNET Primary 32 F 31,5 117,7 NED −
R74 PNET Primary 27 M 110,4 110,4 NED −
R75 PNET Primary 14 M 9,8 25,4 Dead −
R78 PNET Primary 11 F 69,5 69,5 NED −
R79 PNET Primary 21 M 127,1 127,1 NED −
R80 PNET Primary 8 F 23,9 68,5 NED −
R81 Ewing Metastasis 24 M 34,4 81,4 Dead +
R83 PNET Metastasis 4 F 70,1 129,1 NED +
R84 Ewing Metastasis 9 M 27,9 41,6 Dead +
Mean 17,9 40,1 57,0
Abbreviations: EFS: event-free survival; OVS: overall survival; NED: no evidence of disease; AWD: alive with disease; −: treatment not received before biopsy:
+: treatment received before biopsy.4 ISRN Oncology
comparison.Twoseparatetestswereconducted,onebetween
the patient and cell line samples and another between the
patient samples and muscle tissues. For both experiments,
the corresponding gene expression collections were prepro-
cessed with Robust Multi-Array Average (RMA) [13], and
the P values of the t-test were corrected for multiple testing
using the q-value procedure [14]. Genes with q-value below
0.01, indicating false discovery rate (FDR) of 1%, and fold
change >1.6 (Ewing patient samples versus cell lines) or
>2.15 (Ewing patient samples versus muscle tissue) were
considered diﬀerentially expressed. The thresholds for the
fold change were derived based on the expression levels
of 14 housekeeping genes (RPS13, RPS20, RPL30, RPL13A,
RPL9, SRP14, RPL24, RPL22, RPS29, RPS16, RPL4, RPL6,
OAZ1, and RPS12) in the same collections, choosing the
lowest fold change not exceeded by any of the housekeeping
genes.
Fisher’s exact test was used to study the association
between inﬂammation and expression, the null hypothesis
beingthatthereisnoconnectionbetweenagenebeingonthe
listofinﬂammationgenesandhavingdiﬀerentialexpression.
Identical test was performed for the list of genes active in
macrophage cells.
2.5. Immunohistochemistry. Avidin-biotin-peroxidase proce-
dure was used for immunostaining. Brieﬂy, ESFT tumour
tissue microarray sections were treated sequentially with
xylene and ethanol to remove paraﬃn. Endogenous perox-
idase activity was blocked by treatment with 3% hydrogen
peroxide in methanol for 30min at RT. No antigen retrieval
wasperformed.Toavoidbackground,afurtherblockingstep
with normal horse serum (Vector Laboratories, Burlingame,
Calif, USA) was performed. C5 and C5aR1 expression was
analysed using anti-C5 goat antiserum (Quidel, San Diego,
Calif; dilution 1:100) and anti-C5R1 rabbit polyclonal
antibody (Abcam, Cambridge, UK; dilution 1:200) and on
tissue microarray (TMA) containing ESFT patient samples
in triplicates. Tissue sections were incubated with secondary
biotinylated antimouse antibody and with an avidin-biotin-
peroxidasecomplex (VectorLaboratories). The ﬁnalreaction
product was revealed by exposure to 0.03% diaminobenzi-
dine (Sigma, St. Louis, Mo, USA) and nuclei were coun-
terstained with Mayer’s hematoxylin (Sigma). Patients were
scored as negative or positive based on immunoreactivity of
the respective antibody on tumour cells. For C5aR1 and C5
expression normal kidney and heart were, respectively, used
as positive control.
2.6. Survival Analysis. For evaluating the prognostic value
of each gene included in the list of nonmalignant (potential
inﬁltrating immune/stromal) cell-derived (n = 10) and
malignant (putatively ESFT) cell-derived genes (n = 22),
we calculated its median expression value from RMA signal
values (log2), and patients were labelled as having high
expression or low expression relative to the median value.
Patient survival analysis was then performed by Kaplan-
Meier and Log Rank methods considering either event-free
survival or overall survival.
3. Results
3.1. Inﬂammatory Genes Are Activated in ESFT Patient
Samples and this Activation Is Characterized Primarily by
Macrophage Gene Activation. Inﬂammatory signals deriving
potentially from nonmalignant stromal cells or tumour-
associated leukocytes were revealed by comparing ESFT
patient samples to Ewing sarcoma cell lines. Our bioinfor-
matic analysis detected that in ESFT patient samples, 38 of
238 (16%) inﬂammatory genes were signiﬁcantly upregu-
lated and 10 of 238 (4%) downregulated (thresholds: q-value
<0.01 and fold change >1.6) (see Figure 1(a)). The number
of expected upregulated and downregulated genes was 18
and 26, respectively. The number of veriﬁed upregulated
inﬂammatory genes was statistically higher (P<0.001)
and the amount of downregulated inﬂammatory genes was
statistically lower (P<0.001) than expected in ESFT
patient samples. Supplemental data 2 lists observed over-
and underexpressed inﬂammation genes including their fold
changes, q-values and P values when ESFT patient samples
werecomparedto ESFT celllines. Macrophagecellactivity in
ESFT tumour microenvironment was studied using t-test on
299macrophage-relatedgenesandperformingacomparison
between ESFT patient samples and cell lines. t-test showed
that 58 of 299 (19%) macrophage genes were signiﬁcantly
upregulated and 11 of 299 (4%) were downregulated in
ESFT samples (see Figure 1(b)). The number of expected
upregulated macrophage genes was 23, and the number
of downregulated genes was 33, which indicates that the
amount of upregulated macrophage genes was statistically
higher (P<0.001) and the amount of downregulated
macrophagegeneswasstatisticallylower(P<0.001)inESFT
patient samples (Figure 1(b)). Thus, the inﬂammatory gene
expression signature in ESFT patient samples is potentially
describedbymacrophagegeneactivation.Supplementaldata
3listsover-andunderexpressedmacrophagegenesincluding
their fold changes, q-values and P values.
3.2. Combining Data from ESFT Patient, Cell Line, and
Normal Muscle Samples Reveals Potentially Important Inﬂam-
matory Genes under In Vivo Conditions. 32 of 238 (13%)
inﬂammatory genes were upregulated and 10 of 238 (4%)
downregulated when ESFT patient samples were compared
to normal skeletal muscle cell samples (thresholds: q-value
<0.01 and fold change >2.15). Supplement 4 lists over-
and underexpressed inﬂammation genes including their
fold changes, q-values and P values. We postulated that
these inﬂammatory genes distinguish ESFT tumour site
from adjacent normal tissue that by large is composed of
muscular tissues surrounding the tumour site. By com-
bining expression data from ESFT patients, cell lines, and
normal muscle tissue samples, we were able to create two
separate lists of genes. The ﬁrst list included 10 genes (see
Table 2) and was composed of genes whose expression was
upregulated both by comparing ESFT patient samples to
cell lines and, additionally, ESFT patient samples to skeletal
muscle tissue samples. These genes represent genes that
are potentially derived from nonmalignant stromal cells or
inﬁltrating immune cells and are distinguishing tumour siteISRN Oncology 5
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Figure 1: Diﬀerentially expressed inﬂammation and macrophage genes in Ewing sarcoma patient samples. (a) Diﬀerentially expressed
inﬂammation genes and (b) macrophage genes by comparing Ewing patient samples (n = 44) to cell lines (n = 11). On Y-axis, the detected
number of inﬂammatory genes and macrophage genes are marked with grey and the number of expected genes with white bar. The level of
statistical signiﬁcance is marked below the bars and a ﬁgure with ∗ indicates a statistically signiﬁcant result.
Table 2: The list of genes deriving from inﬁltrating immune or nonmalignant stromal cells (n = 10): The diﬀerences in gene expression
between patient tumour sample and cell lines or between patient tumour sample and normal muscle tissue.
Gene
name Comparison Log ratio Fold change q-value P value
SPP1 versus cell lines 5,608 48,757 1,22E-17 2,62E-20
versus muscle 4,823 28,308 9,28E-19 7.30E-19
CXCR4 versus cell lines 3,870 14,621 2,00E-04 7,55E-05
versus muscle 3,700 12,999 9,52E-22 4,67E-22
CD14 versus cell lines 3,089 8,509 8,47E-15 4,10E-17
versus muscle 2,431 5,391 6,04E-15 8,62E-15
FOS versus cell lines 2,984 7,911 5,19E-05 1,44E-05
versus muscle 2,346 5,086 1,37E-04 9,04E-04
TNFAIP3 versus cell lines 2,065 4,186 3,65E-05 9,29E-06
versus muscle 1,411 2,659 1,46E-09 4,86E-09
SOCS3 versus cell lines 1,940 3,837 1,30E-08 6,82E-10
versus muscle 1,793 3,464 6,81E-09 2,50E-08
HSPA6 versus cell lines 1,584 2,998 1,03E-07 7,79E-09
versus muscle 1,353 2,554 8,41E-08 3,65E-07
IL8 versus cell lines 1,368 2,582 1,55E-03 9,18E-04
versus muscle 1,500 2,828 1,02E-07 4,49E-07
IL23A versus cell lines 1,259 2,393 1,13E-05 2,20E-06
versus muscle 1,336 2,525 9,77E-14 1,70E-13
STAT2 versus cell lines 1,259 2,393 1,13E-05 2,20E-06
versus muscle 1,336 2,525 9,77E-14 1,70E-136 ISRN Oncology
Table 3: The list of malignant cell derived inﬂammatory genes (n = 22): The diﬀerences in gene expression between patient tumour sample
a n dn o r m a lm u s c l et i s s u e .
Gene name Log ratio Fold change q-value P value
LY96 4,465 22,085 1,26E-27 2,07E-28
MIF 3,843 14,352 1,01E-32 5,59E-34
JAK1 2,961 7,786 7,06E-24 2,41E-24
MAPK7 2,790 6,917 7,33E-17 7,77E-17
PGLYRP2 2,589 6,017 9,29E-15 1,37E-14
ERLIN1 2,235 4,709 5,16E-16 6,23E-16
PELI1 2,117 4,337 2,33E-14 3,65E-14
SOCS4 2,053 4,149 7,78E-15 1,13E-14
TRAF5 1,984 3,955 4,29E-17 4,38E-17
IRF3 1,889 3,703 3,54E-14 5,73E-14
MYD88 1,846 3,596 1,07E-17 9,93E-18
SOCS2 1,801 3,485 3,21E-11 8,29E-11
STAT6 1,656 3,151 1,93E-13 3,52E-13
HMGB1 1,585 2,999 8,87E-13 1,79E-12
MAPK1 1,447 2,727 7,10E-13 1,40E-12
IL10RB 1,278 2,426 2,16E-11 5,42E-11
IKBKB 1,199 2,296 7,47E-08 3,21E-07
PELI2 1,191 2,283 9,01E-09 3,37E-08
C5 1,185 2,273 2,48E-08 9,92E-08
MAP4K4 1,182 2,268 2,69E-11 6,85E-11
STAT1 1,139 2,202 4,11E-09 1,46E-08
FOXP3 1,112 2,161 6,34E-14 1,07E-13
from surrounding normal tissue. A second list included 22
genes (see Table 3)a n dw a sc o m p o s e do fu p r e g u l a t e dg e n e s
that were obtained by comparing ESFT patient samples to
skeletal muscle tissue samples but were not upregulated
by comparing ESFT patient samples with cell lines. These
genes were assumed to represent inﬂammatory genes that
distinguish ESFT tumours from surrounding normal tissues
in vivo, but are derived from malignant component of
tumour samples, that is, Ewing sarcoma cells.
3.3. High Expression of C5 in ESFT Is a Prognostic Factor
for Favourable Clinical Outcome. Next, we clariﬁed, whether
inﬂammation-associated genes (See Tables 2 and 3) are asso-
ciated with patient prognosis. The best correlation between
expression and patient survival was seen on complement
component C5 belonging to the genes that did not diﬀer
between patient samples and ESFT cell lines but whose
expression was high at tumour site compared to adjacent
normal tissue (see Table 3). High expression of C5 associated
with better event free survival (P = 0.01) and overall
survival (P = 0.004) in a dose-dependent manner in Ewing
sarcoma (n = 44) (see Figures 2(a) and 2(b)). In addition
to C5, high expression of JAK1 (see Table 3) correlated with
favorable overall survival (P = 0.04) across all samples
(Figure 2(c)). IL8 was included in immune or nonmalignant
stromal cell-derived gene list (Table 2) and high expression
of IL8 correlated with reduced overall survival (P = 0.04) in
classical Ewing sarcoma (n = 33) (Figure 2(d)).
3.4. C5 and, Its Receptor, C5aR1 Expression at Protein Level
is Detected in Ewing Sarcoma Cells of ESFT Patient Samples.
The results of the C5 gene expression were veriﬁed in an
independent group of ESFT patients. In this context, we
performed an immunohistochemical analysis on ESFT tissue
microarray to validate the data on protein level and also
to decipher whether ESFT cells express C5 and its receptor
C5aR1. Of the 83 sections scored, 50 (60%) were positive,
and 33 (40%) were negative for C5 protein expression. For
C5 receptor, of the 255 sections scored with C5aR1 antibody,
142 (56%) were positive and 113 (44%) were negative for
C5aR1 expression (Figure 3). As shown in Figures 3(c) and
3(d), malignant cells in tissue sections were positive for
C5 and C5aR1, whereas the matrix stromal cells composed
mainlyofﬁbroblastsweremostlynegativeforC5andC5aR1.
However, weak positivity for C5aR1 in matrix was detected,
as shown in Figure 3(d).
4. Discussion
Extensive research has shown that stroma and inﬁltrating
cells within the tumour microenvironment play an impor-
tant role in tumour biology [1, 15]. In this respect, our studyISRN Oncology 7
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Figure 2: Correlation of inﬂammatory gene expression to ESFT patient survival. Kaplan-Meier analysis shows (a) event-free survival (EFS),
(b)overallsurvival(OVS)ofallESFTpatients(n = 44)accordingtoC5expression,(c)overallsurvivalofallEwingsarcomapatients(n = 44)
according to JAK1 expression, and (d) overall survival of classical Ewing sarcoma patients (n = 33) according to IL8 expression.
was designed to elucidate the inﬂammatory microenviron-
ment in ESFT using microarray-based expression analysis
and bioinformatic tools. The expression analysis was per-
formed on 44 ESFT patients, which is a substantial amount
of samples in this rare tumour entity, and furthermore, the
results concerning C5 were validated on an independent
set of ESFT samples on tumour tissue microarray by
immunohistochemistry. The results suggest that in ESFT,
inﬂammatory genes are activated and that the inﬂammatory
component is characterized mainly by genes related to
macrophages. In addition, the survival analysis showed that
high local expression of C5 and JAK1 was beneﬁcial for ESFT
patient survival, whereas high expression of IL8 correlated
with poor outcome.
In our previous study, we found that in paediatric solid
tumours, including ESFTs, the predominant inﬁltrating
cells were CD68+ macrophages, which accumulated in
these tumours at the areas of necrosis [6]. Accordingly, in
this study, a signiﬁcant enrichment of macrophage-related
gene expression was detected, suggesting that macrophages
inﬁltrate ESFT site in vivo. This strengthens the results of
previous studies also by others [16, 17]. Tumour-associated
macrophages (TAMs) are key regulators between inﬂam-
mation and cancer, and they are engaged in various steps
of tumour progression for example by contributing tumour
growth and angiogenesis by releasing growth factors and
even by incurring immunosuppression [1, 18]. Macrophages
are known to be active in phagocytosis of necrotic/apoptotic8 ISRN Oncology
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(c) (d)
Figure 3:ImmunohistochemicalstainingofC5andC5aR1onESFTtissuemicroarray.(a)NegativestainingofC5inEwingsarcomacells;(b)
Negative staining of C5aR1 in Ewing sarcoma cells; (c) Positive cytoplasmic staining of C5 in Ewing sarcoma cells; (d) Positive cytoplasmic
and membrane staining of C5aR1 in Ewing sarcoma cells and weak positivity in matrix including ﬁbroblasts. Original magniﬁcation ×400.
tumour tissue, but additionally, recent ﬁndings suggest that
TAMs present in ESFTs might diﬀerentiate by RANKL-
and TNF-α-dependent mechanism to osteoclasts, which
in turn participate in the bone resorption as a pathogenic
mechanism of tumour osteolysis [19].
ESFTs usually develop in bone; however, they may
arise also from soft tissues in which case they are called
extraosseous Ewing’s sarcoma. Even, with a primary tumour
that originates intraosseously, a soft-tissue component is
frequently present owing to local invasion into adjacent
muscular tissue through the cortical plate. We postulated
that by comparing the inﬂammatory gene expression of
E S F Ts a m p l e sw i t ht h a to fn o r m a lm u s c l es a m p l e s ,w ec o u l d
ﬁnd genes that are distinguishing and characterizing the
tumour site in vivo from surrounding normal (=muscular)
tissue. These particular genes might involve, for example,
chemokines, chemokine receptors, suppressive factors, or
danger-associated molecular patterns (DAMPs). By identify-
ing highly upregulated ESFT-associated inﬂammatory genes
and connecting their expression levels with prognosis of
patients, it might be possible to ﬁnd new candidate genes for
drug development.
Ourresearchstrategyresultedalistof32ESFT-associated
genes that were further separated into two groups: (a)
nonmalignant inﬂammatory or stromal cell-derived genes
(Table 2) and (b) the genes derived from malignant trans-
formed cells within the tumour tissue (Table 3). The fold
change was highest (28.3) for SPP1 (osteopontin) that is
one of the major extracellular matrix proteins in bone and
is produced by numerous cell types including osteoblasts
and osteoclasts, but also by NK cells, T cells, macrophages,
and cancer cells [20, 21]. High expression of SPP1 in
tumour samples but not in cell lines (see Table 2) suggests
that this gene is mostly expressed by stromal cells and
other inﬁltrating cells within tumours but not by ESFT-cells
themselves. In spite of its high expression, SPP1 (or some
other highly expressed genes, e.g., CXCR4) did not correlate
with patient survival, which could be explained by several
ways. For example, if the majority of tumours are almost
uniformly expressing some particular genes and related
proteins, the inﬂuence of the variation in their expression
level may not be easily detected. This may be the case also
with chemokine receptor CXCR4, which was another gene
that was strongly expressed in ESFT primary tumor samples.
CXCR4 together with its cognate ligand CXCL12 (stromal
cell-derived factor-1/SDF-1) is widely expressed in various
diﬀerent cancers, and it is somewhat surprising that its
expression did not correlate with patient survival. It is also
possible that high gene expression is not related with any
such critical functions that have profound impact on patient
survival. Thus, high gene expression does not necessarily
mean that a gene or related protein is a good drug targetISRN Oncology 9
nor does the lack of correlation between a gene, and patient
survival implicates that the gene does not play a role in
tumour progression in vivo.
The survival analysis showed that high expression of
IL8, also known as CXCL8, associates with unfavourable
survival in classical Ewing sarcoma of bone. IL8 is known
to be a highly proinﬂammatory chemokine, which binds to
CXCR1 and CXCR2. In the tumour microenvironment, IL8
has shown to contribute tumour growth and progression by
enhancingtumourcellproliferationandsurvival,topromote
angiogenesis by activating endothelial cells, and ﬁnally to
facilitatemetastasisbyenhancingcellinvasionandmigration
[22]. In this context, our results suggesting the prognostic
signiﬁcance of IL8 and in ESFT are plausible and further
strengthen the current view of IL8 function in tumour
biology.
JAK1 and complement component C5 are important
proteins involved with early steps of acute inﬂammation.
JAK1 is a protein tyrosine kinase that mediates initial steps of
interferon-α,- β,a n d- γ signal transduction. Interferons are
produced at early steps of acute inﬂammation for example,
by natural killer cells (NKs) and plasmacytoid dendritic cells
(DCs) and one of their main roles is activation of tumour
killing functions of macrophages. Type I interferons are
also used in the treatment of various cancers in clinic. Our
data indicates that high expression of JAK1 correlates with
favourable clinical outcome in ESFT, and it suggests that at
least in some patients an advantageous acute inﬂammatory
reaction is ongoing in tumour tissue. One should bear
in mind, however, that mutations in JAK1 resulting in its
constitutive activation have been suggested to be the initial
d e f e c t si ns e v e r a lh u m a nc a n c e r s[ 23] and inhibition of JAK1
has been shown to induce apoptosis and to reduce tumour
cell invasion in colorectal cancer cells [24].
To our knowledge, this paper is the ﬁrst to show an
association between locally produced C5 expression and
favourable patient survival in human cancers. The results
on immunohistochemistry provided an independent veriﬁ-
cation of the gene expression analysis of C5. C5 is a part of
the complement cascade system that initiates acute inﬂam-
matory responses. The activation of complement system
results in the cleavage of C5 to its active subcomponents
C5a and C5b. C5a is an anaphylatoxin, which is a powerful
inﬂammatory mediator with chemotactic activity especially
for neutrophils, but also for monocytes and macrophages
[25]. On the other hand, C5b forms together with C6, C7,
C8andC9acomplementmembraneattackcomplex(MAC),
which ultimately leads to the lysis of the target cell. Even
though the complement system has been conventionally
considered to present a part of innate immune system,
accumulating data suggests that complement system and
C5a are able to activate cells involved in both innate and
adaptive immunity [26]. Locally produced C5a did augment
naive T cell survival and proliferation [27] and additionally
enhanced T cell viability and expansion by suppressing
antigen-induced programmed cell death [28]. Interestingly,
in a previous study, C5a in a tumour microenvironment
promoted tumour growth by activation of myeloid-derived
suppressor cells [29]. It should be underlined, however, that
t h i so b s e r v a t i o nw a sm a d ei nam o u s em o d e lo fc e r v i c a l
cancer. The observation of the expression of both C5 and
C5aR1 in ESFT cells is very interesting and indicates that
an autocrine loop might be present. C5a is a powerful
proinﬂammatory factor and triggers release of DAMPs from
target cells. Of interest, mesenchymal stem cells, from
which ESFTs are suggested to be originating from, express
C5aR1 and its activation by C5a cause prolonged ERK1/2
phosphorylation [30]. Further eﬀorts should be taken on
what C5 activation elicits on ESFT cells and which kind of
downstream signalling pathways are triggered. Ultimately,
the function of C5 in ESFT and other tumour types needs
to be investigated more profoundly, and its role in tumour
biology remains to be elucidated.
5. Conclusion
Our results suggest that even in cancers of noninﬂammatory
origin like ESFTs an macrophage-enriched inﬂammatory
microenvironment that distinguishes the tumour site from
normal adjacent tissue is present at the time of clinically
evident disease. Further, our results pointed out several
prognosticallysigniﬁcantinﬂammation-associatedgeneslike
C5, JAK1 and IL8. To our knowledge, this paper is the
ﬁrst to show an association between locally produced C5
expressionandfavourablepatientsurvivalinhumancancers.
Taken together, our ﬁndings suggest that immune cells and
especially C5 have an important role in controlling the
progression of ESFT and that C5 can be used as a clinically
signiﬁcant prognostic factor for ESFT patients.
Funding
The authors gratefully acknowledge the ﬁnancial support
received from European Commission (EuroBoNeT LSHC-
CT-2006-018814), Helsinki University Central Hospital,
Finnish Cultural Foundation, and Maud Kuistila’s Memorial
Foundation.
Conﬂict of Interests
The authors declare that they have no conﬂict of interests.
Acknowledgment
The authors would like to thank Dr. P¨ aivi Heikkil¨ af o r
her excellent help with evaluation and analysis of tissue
microarray sections.
References
[ 1 ]J .V a k k i l aa n dM .T .L o t z e ,“ I n ﬂ a m m a t i o na n dn e c r o s i s
promote tumour growth,” Nature Reviews Immunology, vol. 4,
no. 8, pp. 641–648, 2004.
[2] W. H. Wang, J. Q. Huang, G. F. Zheng, S. K. Lam, J. Karlberg,
andB.C.Y.Wong,“Non-steroidalanti-inﬂammatorydruguse
and the risk of gastric cancer: a systematic review and meta-
analysis,” Journal of the National Cancer Institute, vol. 95, no.
23, pp. 1784–1791, 2003.10 ISRN Oncology
[3] A. Gonzalez-Perez, L. A. Garcia Rodriguez, and R. Lopez-
Ridaura,“Eﬀectsofnon-steroidalanti-inﬂammatorydrugson
cancer sites other than the colon and rectum: a meta-analysis,”
BMC Cancer, vol. 3, no. 28, 2003.
[4] E. S. Schernhammer, J. H. Kang, A. T. Chan et al., “A
prospective study of aspirin use and the risk of pancreatic
cancer in women,” Journal of the National Cancer Institute, vol.
96, no. 1, pp. 22–28, 2004.
[ 5 ] D .S .D i c k e n s ,R .K o z i e l s k i ,P .J .L e a v e y ,C .T i m m o n s ,a n dT .P .
Cripe, “Cyclooxygenase-2 expression does not correlate with
outcome in osteosarcoma or rhabdomyosarcoma,” Journal of
Pediatric Hematology/Oncology, vol. 25, no. 4, pp. 282–285,
2003.
[ 6 ]J .V a k k i l a ,R .J a ﬀe, M. Michelow, and M. T. Lotze, “Pediatric
cancers are inﬁltrated predominantly by macrophages and
contain a paucity of dendritic cells: a major nosologic
diﬀerence with adult tumors,” Clinical Cancer Research, vol.
12, no. 7, pp. 2049–2054, 2006.
[7] P. Rosito, A. F. Mancini, R. Rondelli et al., “Italian cooperative
study for the treatment of children and young adults with
localized ewing sarcoma of bone: a preliminary report of 6
years of experience,” Cancer, vol. 86, no. 3, pp. 421–428, 1999.
[8] G. Bacci, A. Balladelli, C. Forni et al., “Adjuvant and neo-
adjuvant chemotherapy for Ewing’s sarcoma family tumors
and osteosarcoma of the extremity: further outcome for
patients event-free survivors 5 years from the beginning of
treatment,” Annals of Oncology, vol. 18, no. 12, pp. 2037–2040,
2007.
[9] S. Savola, A. Klami, A. Tripathi et al., “Combined use of
expressionandCGHarrayspinpointsnovelcandidategenesin
Ewing sarcoma family of tumors,” BMC Cancer, vol. 9, article
17, 2009.
[10] T.Barrett,D.B.Troup,S.E.Wilhiteetal.,“NCBIGEO:mining
tens of millions of expression proﬁles—database and tools
update,” NucleicAcidsResearch,vol. 35, no. 1, pp.D760–D765,
2007.
[11] A. I. Su, M. P. Cooke, K. A. Ching et al., “Large-scale analysis
of the human and mouse transcriptomes,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 99, no. 7, pp. 4465–4470, 2002.
[ 1 2 ]E .B i r n e y ,T .D .A n d r e w s ,P .B e v a ne ta l . ,“ A no v e r v i e wo f
Ensembl,” Genome Research, vol. 14, no. 5, pp. 925–928, 2004.
[13] R. A. Irizarry, B. Hobbs, F. Collin et al., “Exploration,
normalization,andsummariesofhighdensityoligonucleotide
array probe level data,” Biostatistics, vol. 4, no. 2, pp. 249–264,
2003.
[14] J. D. Storey and R. Tibshirani, “Statistical signiﬁcance for
genomewide studies,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 100, no. 16, pp.
9440–9445, 2003.
[15] L. M. Coussens and Z. Werb, “Inﬂammation and cancer,”
Nature, vol. 420, no. 6917, pp. 860–867, 2002.
[16] T. Loning, J. Liebsch, and G. Delling, “Osteosarcomas and
Ewing’s sarcomas. Comparative immunocytochemical inves-
tigation of ﬁlamentous proteins and cell membrane determi-
nants,” Virchows Archiv, vol. 407, no. 3, pp. 323–336, 1985.
[17] A. Mantovani, S. Sozzani, M. Locati, P. Allavena, and A. Sica,
“Macrophage polarization: tumor-associated macrophages as
a paradigm for polarized M2 mononuclear phagocytes,”
Trends in Immunology, vol. 23, no. 11, pp. 549–555, 2002.
[18] C. E. Lewis and J. W. Pollard, “Distinct role of macrophages in
diﬀerent tumor microenvironments,” CancerResearch,vol.66,
no. 2, pp. 605–612, 2006.
[19] Y. S. Lau, I. E. Adamopoulos, A. Sabokbar, H. Giele, C. L.
M. H. Gibbons, and N. A. Athanasou, “Cellular and humoral
mechanisms of osteoclast formation in Ewing’s sarcoma,”
British Journal of Cancer, vol. 96, no. 11, pp. 1716–1722, 2007.
[20] A. O’Regan and J. S. Berman, “Osteopontin: a key cytokine
in cell-mediated and granulomatous inﬂammation,” Interna-
tional Journal of Experimental Pathology, vol. 81, no. 6, pp.
373–390, 2000.
[21] L. F. Brown, A. Papadopoulos-Sergiou, B. Berse et al., “Osteo-
pontin expression and distribution in human carcinomas,”
American Journal of Pathology, vol. 145, no. 3, pp. 610–623,
1994.
[22] D. J. J. Waugh and C. Wilson, “The interleukin-8 pathway in
cancer,” Clinical Cancer Research, vol. 14, no. 21, pp. 6735–
6741, 2008.
[23] J. Staerk, A. Kallin, J. B. Demoulin, W. Vainchenker, and S.
N.Constantinescu,“JAK1andTyk2activationbythehomolo-
gouspolycythemiaveraJAK2V617Fmutation:cross-talkwith
IGF1 receptor,” Journal of Biological Chemistry, vol. 280, no.
51, pp. 41893–41899, 2005.
[24] H. Xiong, Z. G. Zhang, X. Q. Tian et al., “Inhibition of
JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest,
and reduces tumor cell invasion in colorectal cancer cells,”
Neoplasia, vol. 10, no. 3, pp. 287–297, 2008.
[ 2 5 ]S .R .M a r d e r ,D .E .C h e n o w e t h ,I .M .G o l d s t e i n ,a n dH .D .
Perez, “Chemotactic responses of human peripheral blood
monocytes to the complement-derived peptides C5a and C5a
des Arg,” Journal of Immunology, vol. 134, no. 5, pp. 3325–
3331, 1985.
[26] R. F. Guo and P. A. Ward, “Role of C5a in inﬂammatory
responses,” Annual Review of Immunology, vol. 2, pp. 821–852,
2005.
[27] M. G. Strainic, J. Liu, D. Huang et al., “Locally produced com-
plement fragments C5a and C3a provide both costimulatory
and survival signals to naive CD4+ T cells,” Immunity, vol. 28,
no. 3, pp. 425–435, 2008.
[28] P. N. Lalli, M. G. Strainic, M. Yang, F. Lin, M. E. Medof, and
P. S. Heeger, “Locally produced C5a binds to T cell expressed
C5aRtoenhanceeﬀectorT-cellexpansionbylimitingantigen-
induced apoptosis,” Blood, vol. 112, no. 5, pp. 1759–1766,
2008.
[29] M. M. Markiewski, R. A. DeAngelis, F. Benencia et al., “Mod-
ulation of the antitumor immune response by complement,”
Nature Immunology, vol. 9, no. 11, pp. 1225–1235, 2008.
[30] I. U. Schraufstatter, R. G. DiScipio, M. Zhao, and S. K.
Khaldoyanidi, “C3a and C5a are chemotactic factors for
human mesenchymal stem cells, which cause prolonged
ERK1/2 phosphorylation,” Journal of Immunology, vol. 182,
no. 6, pp. 3827–3836, 2009.